Strategic acquisitions are the dominant MedTech exit. Large medtechs (Medtronic, J&J, Stryker, Abbott, Boston Scientific, Intuitive, Edwards) acquire to fill pipeline gaps, enter adjacent segments, or absorb disruptive technology. Deal structures often include upfront cash plus earn-outs tied to regulatory and revenue milestones. Acquirers often buy device companies after key clinical or regulatory milestones to reduce risk. Deals may include upfront payments plus milestone earnouts. Due diligence covers regulatory status, quality systems, IP, reimbursement and cybersecurity.

Why it matters

IPO is rare relative to M&A in MedTech. Buyer selection, pipeline fit, and milestone structure shape outcomes for founders and investors.

Common pitfalls

•Failing to conduct comprehensive regulatory due diligence on the acquired company's products and quality system can lead to costly post-acquisition remediation efforts.
•Neglecting to integrate the acquired company's design and production controls into the acquirer's quality management system can result in non-compliance.
•Underestimating the resources required for post-acquisition remediation of regulatory deficiencies is a common mistake.
•Assuming that the acquired company's existing regulatory clearances or certifications automatically transfer without review is incorrect.
•Not assessing the cybersecurity posture of acquired products and systems can introduce significant risks to the acquiring organization.

Sources

EY MedTech M&A · EY
AHRMM - Healthcare Supply Chain · AHRMM
AdvaMed Code of Ethics · AdvaMed
FTC, Premerger Notification and the Merger Review Process · FTC

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.